1. Home
  2. DHIL vs PRTC Comparison

DHIL vs PRTC Comparison

Compare DHIL & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamond Hill Investment Group Inc.

DHIL

Diamond Hill Investment Group Inc.

N/A

Current Price

$172.65

Market Cap

463.8M

Sector

Finance

ML Signal

N/A

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$17.32

Market Cap

464.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DHIL
PRTC
Founded
1990
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.8M
464.3M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
DHIL
PRTC
Price
$172.65
$17.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.7K
3.5K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
3.48%
N/A
EPS Growth
14.37
N/A
EPS
17.91
N/A
Revenue
$145,201,729.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.64
$8.09
Revenue Growth
6.69
N/A
52 Week Low
$114.11
$13.30
52 Week High
$173.00
$20.00

Technical Indicators

Market Signals
Indicator
DHIL
PRTC
Relative Strength Index (RSI) 69.23 48.59
Support Level $170.59 $16.51
Resistance Level N/A $18.10
Average True Range (ATR) 0.76 0.49
MACD -0.11 -0.08
Stochastic Oscillator 90.52 44.66

Price Performance

Historical Comparison
DHIL
PRTC

About DHIL Diamond Hill Investment Group Inc.

Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: